AAO 2026 Recap + Vitrectomy for Floaters with Christina Weng, MD, MBA

10/16/26

Guest: Christina Y. Weng, MD, MBA: Professor & Alice R. McPherson Retina Research Foundation Chair in Ophthalmology, Baylor College of Medicine, and host of the Retina TL;DR podcast

 

Topics Covered

 

AAO 2026: What Had the Room Buzzing

 

Zenkuda (Kodiak Sciences): Phase 3 DAYBREAK confirmed noninferiority to aflibercept in wet AMD. 54% of patients reached 6-month dosing under strict treat-to-dryness retreatment criteria. Kodiak plans a multi-indication BLA in Q4 2026 across wet AMD, DR, and RVO. Tabirafusp-ted also met its noninferiority endpoint. The IL-6 rationale is weaker in wet AMD than in DME or uveitis.

 

Remigromig (Merck): Donald J. D'Amico, MD, presented BRUNELLO one-year results. Visual acuity gains were noninferior to monthly ranibizumab in DME. New-onset PDR appeared in roughly 6.5% of remigromig patients versus under 1% with ranibizumab. Remigromig doesn't cause PDR. It just doesn't suppress it the way anti-VEGF does. Tiespectus (MK-8748) is now enrolling in the pivotal MALBEC trial for wet AMD.

 

Vamikibart (Genentech/Roche): One-year MEERKAT and SANDCAT data showed sustained improvement in uveitic macular edema. The FDA accepted the BLA, with an approval decision expected July 2027. It would be the first non-steroidal intravitreal treatment for uveitic macular edema.

 

Laru-zova (Beacon Therapeutics): Robert Sisk, MD, presented VISTA Phase 3 results. In the high-dose arm, 31% gained 15+ letters in low luminance VA. Low-dose: 24%. Untreated control: 0%. A rolling FDA submission is planned. If approved, it would be the first ocular gene therapy since Luxturna in 2017.

 

PRIMA Photovoltaic Retinal Implant: The safety update showed trade-offs more favorable than expected. European approval is active, and FDA review is possible before the end of 2026. Patients average 62 hours of post-implant training before functional benefit.

 

SJJ Solutions: John previewed a pre-launch suprachoroidal access device designed to guide standard needle placement reliably regardless of scleral thickness.

 

Vitrectomy for Floaters with Christina Y. Weng, MD, MBA

 

Three drivers behind the cultural shift: patients with debilitating symptoms are raising awareness through word of mouth, the premium IOL era has raised the bar on visual quality, and advances in surgical technology have improved the risk-benefit ratio on both sides.

 

Patient selection: Christina requires at least six months of symptoms before operating. Ideal candidate: symptomatic, pseudophakic, complete PVD, few comorbidities, realistic expectations. In phakic patients, she often defers until after cataract surgery or proposes combined surgery. Jerry Sebag, MD's contrast sensitivity research, showing vitreous opacities can degrade contrast sensitivity comparably to a 2-3+ nuclear sclerotic cataract, has supported insurance coverage. This is not cash-pay elective surgery.

 

Academic centers have been slower to adopt, partly clinical stigma, partly reimbursement pressure. Christina is candid that declining reimbursements and OR access constraints shape case mix decisions everywhere. The shift toward elective vitreoretinal surgery at academic centers is real and compatible with patient-first priorities.

 

Key Takeaways

 

Zenkuda's strict treat-to-dryness protocol yielded 54% six-month durability. Kodiak is filing across three indications simultaneously in Q4 2026.

 

Remigromig doesn't cause PDR. It just doesn't treat it. Combination use with anti-VEGF is the likely path forward.

 

Vamikibart could give uveitic macular edema patients their first non-steroidal intravitreal option. FDA decision expected July 2027.

 

Laru-zova may be the second approved ocular gene therapy in a decade. For some XLRP patients who've been told there's nothing, the conversation has changed.

 

Vitrectomy for floaters works, insurance covers it, and the risk-benefit math is better than ever. The remaining hurdle is cultural, and that's shifting.

 

Sponsors

 

This episode is made possible by Genentech, maker of Vabysmo (faricimab-svoa). Purple Chair series at vabysmo-hcp.com.

 

This episode is brought to you by Alcon, including Unity VCS. Learn more at unityvcs.com.

 

Astellas is focused on patients whose lives are impacted by declining or lost vision. Learn more at Astellas.com.

 

Credits

 

Production & Marketing: Laura Brown | Business Operations: Liz Hogan

 

🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube

Previous

Breaking News: LUCIA Misses in Wet AMD — EyePoint Shifts to DME

Next

The 2026 Data Recap — What to Watch at AAO Next Week